The combined administration of FF with SLM did not change the beneficial hypolipidemic effects of FF, and in addition, reduced lipoperoxidation, the gene expression of CYP4A1 and CYP2E1 involved in the reduction in pro-inflammatory activity, and the production of ROS, and thus decreased the risk of developing complications of hepatic steatosis. Here, CYP2E1 is linked to fatty liver disease.